Abstract: Four new strains of Bacillus thuringiensis are disclosed which are active against Coleoptera. The novel strains are identified through PCR technology using mixtures of carefully selected oligonucleotide primers that aid in the prediction of insect toxicity profile for the proteins produced by the strains.

Abstract: cDNA sequences are disclosed which are expressed specifically in the anther of a plant. Genomic DNA sequences corresponding to the cDNA clones are obtained using the cDNA clones as hybridization probes. Recombinant, or chimeric, DNA sequences are constructed in which the promoter sequence from anther-specific genomic clones are operatively linked to a DNA sequence coding for a desired polypeptide. Transgenic plants are made in which the chimeric DNA sequences are expressed in the anther of the transgenic plant. In a preferred embodiment, the coding DNA sequence expresses a polypeptide which will disrupt formation of viable pollen, resulting in a male-sterile plant.

Abstract: DNA sequences are able to function as promoters of tissue-preferential transcription of associated DNA sequences in plants, particularly in the roots. These DNA sequences can be used in transformation vectors to produce transgenic plants which will express the heterologous genes preferentially in tissue, particularly in the roots of maize plants.

Abstract: The invention concerns polypeptides with an apparent molecular weight of around 160 kD which are mediators or precursors for mediators of inflammation, derivatives thereof such as mutants and fragments, processes for their preparation, DNAs and hybrid vectors coding for said polypeptides and derivatives and host cells transformed with such hybrid vectors, polyclonal and monoclonal antibodies specific for said polypeptides or their derivatives and antibody derivatives as well as diagnostic and therapeutic methods for inflammatory conditions and Hodgkin lymphomas.

Abstract: The present invention relates to pharmaceutical compositions comprising a combination of two different plasminogen activators which are used for the prophylaxis and therapie of thrombosis.

Abstract: The present invention provides a dual method for producing male-sterile plants. Two genetically transformed plants, parents 1 and 2 are crossed to obtain male-sterile offspring. Parent 1 is transformed with an expression cassette comprising a nucleotide sequence encoding an anther-specific promoter which is operably linked to a nucleotide sequence encoding a transactivator. Parent 2 is transformed with an expression cassette comprising a target nucleotide sequence, which is capable of being activated by the transactivator, operably linked to a nucleotide sequence which encodes RNA or a polypeptide which will disrupt the formation of viable pollen. Therefore, crossing parent 1 with parent 2 results in male-sterile offspring. The male-sterile plants are useful for producing hybrid seed.The invention also provides compositions and methods for high level expression of a coding region of interest in a plant.

Abstract: IgE binding factors (IgE-bfs) with IgE suppressor (IgE-SF) activity obtainable from human colostrum in an enriched form, a method for the prevention and/or the treatment of allergy by administering the IgE-bfs and pharmaceutical compositions comprising said IgE-bfs.

Abstract: Anti-pathogenically effective compositions are provided containing a combination of hydrolytic enzymes and lytic peptides as the active agent. Methods of controlling the growth of pathogens using the anti-pathogenically effective compositions are provided. Transgenic plants that contain genes that are able to express lytic peptides and hydrolytic enzymes are also provided.

Abstract: Purified bacterial strains that are effective for the inhibition of plant pathogens, including the fungi Rhizoctonia solani and Pythium ultimum have been isolated. These strains are useful as biocontrol agents, and can be used to produce antifungal metabolites, such as antibiotic compounds, active against the plant pathogenic fungi Rhizoctonia solani and Pythium ultimum. Both the purified bacterial strains and the antibiotic compounds can be used as active agents for biocontrol compositions.

Abstract: The invention concerns monoclonal antibodies which are directed against the thrombin/hirudin-complex and derivatives thereof, processes for their preparation, hybridoma cell lines secreting said monoclonal antibodies, and processes for the preparation of the hybridoma cell lines. Furthermore, the invention relates to the use of the monoclonal antibodies and/or their derivatives for the determination of the thrombin/hirudin-complex as well as to test kits comprising said monoclonal antibodies and/or their derivatives.

Abstract: The invention concerns a process for the preparation of hybridoma cells which secrete monoclonal antibodies specific for hirudin, the hybridoma cells themselves, the monoclonal antibodies specific for hirudin secreted by these hybridoma cells, derivatives thereof, and a process for the preparation of said antibodies and derivatives. These monoclonal anti-hirudin antibodies and their derivatives are useful for the determination of hirudin and as an antidote to hirudin. The invention also concerns test kits and pharmaceutical compositions comprising said monoclonal antibodies and/or derivatives.

Abstract: A process for the preparation of a recombinant IGF-II (rIGF-II) without a covalently attached foreign protein moiety and without N-terminal attached methionine or a derivative of methionine or of a salt of said IGF-II, rIGF-II produced by said method, hybrid vectors comprising DNA encoding said rIGF-II, hosts transformed with said vectors, and a process for the isolation of said rIGF-II from the host cell and refolding it into a biologically active form.

Abstract: Four new strains of Bacillus thuringiensis are disclosed which are active against Coleoptera. The novel strains are identified through PCR technology using mixtures of carefully selected oligonucleotide primers that aid in the prediction of insect toxicity profile for the proteins produced by the strains.

Abstract: The invention concerns a peptidylhydroxyglycine N-C lyase (PHL) catalyzing the reactionR-GlyOH.fwdarw.R-NH.sub.2wherein R represents a peptide residue, and GlyOH represents an .alpha.-hydroxyglycine residue linked to the C-terminus of said peptide R by an amide bond, a recombinant DNA molecule coding for a PHL, a method for the preparation of such a recombinant DNA molecule, processes for the preparation of PHL from a natural source or by means of the said recombinant DNA molecule, and the use of PHL for the preparation of an amidated peptide R-NH.sub.2.

Abstract: Retroviral vaccines are provided comprising incompetent retroviruses containing defective RNA produced by growing viral transformed cells in the presence of interferon. The resulting defective viruses by themselves or in combination with interferon can be used as vaccines for immunizing viral sensitive hosts against infection. A novel feline interferon is produced in culture with cells infected with the defective non-infectious retroviruses.